Adherence with intravenous zoledronate and intravenous ibandronate in the United States medicare population

摘要: Objective To evaluate adherence to drug therapy among new users of zoledronate and intravenous (IV) ibandronate US Medicare enrollees. Methods We used data from the 5% random sample IV with continuous Part A B fee-for-service coverage. The outcome was as quantified by proportion days covered (PDC) measured continuously dichotomously (≥80%). Followup time extended 18–27 months for all individuals. Factors associated low were evaluated logistic regression. Results We identified 775 846 ibandronate. For both drugs, 30–48% first infusions given in an outpatient infusion center, not a physician's office. mean PDC 82%, which greater than (58–62% depending on period; P < 0.0001). Approximately 30% did receive second infusion. included older age receipt center rather office. Conclusion Less frequently dosed bisphosphonates have resolved problem suboptimal prescription osteoporosis medications. Interventions continue be warranted improve long-term treatments.